IRIS
ELENA, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.261
EU - Europa 879
AS - Asia 611
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
SA - Sud America 1
Totale 2.763
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.248
CN - Cina 544
IE - Irlanda 384
FI - Finlandia 124
UA - Ucraina 90
IT - Italia 87
DE - Germania 79
SG - Singapore 50
SE - Svezia 37
GB - Regno Unito 26
BE - Belgio 17
FR - Francia 17
CA - Canada 13
AU - Australia 5
IN - India 5
JP - Giappone 4
NL - Olanda 4
PL - Polonia 4
RU - Federazione Russa 4
EU - Europa 3
AZ - Azerbaigian 2
HK - Hong Kong 2
AT - Austria 1
BR - Brasile 1
DK - Danimarca 1
EG - Egitto 1
GR - Grecia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RO - Romania 1
TR - Turchia 1
Totale 2.763
Salva come PNG Salva come JPEG
Città #
Dublin 384
Chandler 240
Nanjing 163
Jacksonville 144
Boardman 112
Ashburn 105
Nanchang 67
Ann Arbor 63
Princeton 59
Lawrence 57
Medford 55
Beijing 53
Wilmington 51
Changsha 45
Helsinki 44
Hebei 38
Singapore 38
Jiaxing 37
Shenyang 35
Pavia 30
New York 28
Shanghai 26
Hangzhou 20
Brussels 17
Tianjin 14
Norwalk 12
Toronto 12
Woodbridge 12
Milan 11
Seattle 8
Jinan 7
Los Angeles 7
Fairfield 5
Falls Church 5
Houston 5
Verona 5
Washington 5
Kunming 4
Ningbo 4
Pune 4
Florence 3
Guangzhou 3
Redwood City 3
Reston 3
San Francisco 3
Taizhou 3
Tappahannock 3
Tokyo 3
Baku 2
Canberra 2
Fuzhou 2
Monza 2
Naples 2
Paris 2
Santa Clara 2
Sesto San Giovanni 2
Zhengzhou 2
Almaty 1
Andover 1
Athens 1
Auburn Hills 1
Auckland 1
Berlin 1
Bolgare 1
Cairo 1
Central 1
Changchun 1
Chongqing 1
Colombo 1
Como 1
Dallas 1
Dearborn 1
Dongyang 1
Haikou 1
Hefei 1
Herne 1
Hong Kong 1
Huzhou 1
Jinhua 1
Lanzhou 1
Leawood 1
London 1
Mainz 1
Mariano Comense 1
Melbourne 1
Noale 1
Orange 1
Piediluco 1
Rome 1
San Giuliano 1
Sassari 1
Shaoxing 1
Stoney Creek 1
São Paulo 1
Tesero 1
Vanzaghello 1
Vientiane 1
Volgograd 1
Wuhan 1
Xingtai 1
Totale 2.116
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 95
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 83
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 79
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 78
Blast phase of essential thrombocythemia: A single center study. 77
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 72
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 70
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 69
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 67
Clinical significance of somatic mutation in unexplained blood cytopenia 65
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 63
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 60
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 60
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 60
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia 59
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 58
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 58
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 57
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 56
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 56
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 54
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 53
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 53
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 51
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 51
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 51
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms 51
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 51
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 50
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 50
Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis 48
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions 48
Mutational status of myeloproliferative neoplasms. 47
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 46
‘Real-life’ study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis 45
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis 44
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 43
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia 43
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 42
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 41
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications 41
Somatic mutations of calreticulin in myeloproliferative neoplasms 41
Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN 40
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 39
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 38
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 38
Incidence and Prognosis of Clonal Hematopoiesis in patients with Chronic Idiopathic Neutropenia 36
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 34
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem? 32
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 32
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. 29
Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry 29
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 28
Relationship between clone metrics and clinical outcome in clonal cytopenia 24
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. 24
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. 24
Validation of cytogenetic-based risk stratification in primary myelofibrosis. 23
Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications 21
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes 20
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series 19
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry 8
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 5
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis 4
Totale 2.933
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020137 0 0 0 0 3 20 5 20 15 43 30 1
2020/2021227 26 19 4 21 2 18 12 40 21 32 21 11
2021/2022294 5 3 3 6 6 7 4 17 13 21 40 169
2022/2023858 79 62 5 45 81 64 0 38 434 7 30 13
2023/2024375 53 61 21 23 27 102 2 30 3 5 8 40
2024/2025167 22 72 26 22 25 0 0 0 0 0 0 0
Totale 2.933